You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDiclofenamide
Accession NumberDB01144  (APRD00131, DB07948)
TypeSmall Molecule
GroupsApproved
DescriptionA carbonic anhydrase inhibitor that is used in the treatment of glaucoma. [PubChem]
Structure
Thumb
Synonyms
1,3-disulfamoyl-4,5-dichlorobenzene
1,3-Disulfamyl-4,5-dichlorobenzene
3,4-Dichloro-5-sulfamylbenzenesulfonamide
4,5-Dichloro-1,3-benzenedisulfonamide
4,5-dichloro-1,3-disulfamoylbenzene
4,5-Dichloro-benzene-1,3-disulfonic acid diamide
4,5-dichloro-m-benzenedisulfonamide
4,5-DICHLOROBENZENE-1,3-disulfonamide
Dichlofenamide
Dichlorophenamide
Dichlorphenamide
Diclofenamida
Diclofenamide
Diclofenamidum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DaranideTablet50 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2012-03-16Not applicableUs
KeveyisTablet50 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2015-08-07Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
OratrolAlcon
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIVVJ6673MHY
CAS number120-97-8
WeightAverage: 305.159
Monoisotopic: 303.914603484
Chemical FormulaC6H6Cl2N2O4S2
InChI KeyGJQPMPFPNINLKP-UHFFFAOYSA-N
InChI
InChI=1S/C6H6Cl2N2O4S2/c7-4-1-3(15(9,11)12)2-5(6(4)8)16(10,13)14/h1-2H,(H2,9,11,12)(H2,10,13,14)
IUPAC Name
4,5-dichlorobenzene-1,3-disulfonamide
SMILES
NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O
Pharmacology
IndicationFor adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure
Structured Indications
PharmacodynamicsDichlorphenamide is an oral carbonic anhydrase inhibitor indicated for adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Carbonic anhydrase inhibitors reduce intraocular pressure by partially suppressing the secretion of aqueous humor (inflow).
Mechanism of actionCarbonic anhydrase inhibitors reduce intraocular pressure by partially suppressing the secretion of aqueous humor (inflow), although the mechanism by which they do this is not fully understood. Evidence suggests that HCO3- ions are produced in the ciliary body by hydration of carbon dioxide under the influence of carbonic anhydrase and diffuse into the posterior chamber which contains more Na+ and HCO3- ions than does plasma and consequently is hypertonic. Water is then attracted to the posterior chamber by osmosis, resulting in a drop in pressure.
TargetKindPharmacological actionActionsOrganismUniProt ID
Carbonic anhydrase 1Proteinyes
inhibitor
HumanP00915 details
Carbonic anhydrase 2Proteinyes
inhibitor
HumanP00918 details
Carbonic anhydrase 4Proteinyes
inhibitor
HumanP22748 details
Carbonic anhydrase 7Proteinyes
inhibitor
HumanP43166 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding55%
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineDiclofenamide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
3,4-MethylenedioxyamphetamineDiclofenamide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
3,4-MethylenedioxymethamphetamineDiclofenamide may decrease the excretion rate of 3,4-Methylenedioxymethamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineDiclofenamide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
AcebutololThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Acebutolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Diclofenamide.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Diclofenamide.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Diclofenamide.Approved
AliskirenThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Aliskiren.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Diclofenamide.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Diclofenamide.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Diclofenamide.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Diclofenamide.Approved, Illicit
AmphetamineDiclofenamide may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Diclofenamide.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Diclofenamide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Diclofenamide.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Azilsartan medoxomil.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Diclofenamide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Diclofenamide.Experimental
BarbitalBarbital may increase the hypotensive activities of Diclofenamide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Diclofenamide.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Diclofenamide.Approved
BenzphetamineDiclofenamide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BepridilThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Diclofenamide.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Diclofenamide.Approved
BortezomibThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Diclofenamide.Approved
BrinzolamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Brinzolamide.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Bromocriptine.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Diclofenamide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Bupivacaine.Approved, Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Diclofenamide.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Captopril.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Diclofenamide.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Carbetocin.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Diclofenamide.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Diclofenamide.Approved, Investigational
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Diclofenamide.Approved, Vet Approved
ChlorphentermineDiclofenamide may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Diclofenamide.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Cilnidipine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Diclofenamide.Approved
ClozapineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Conivaptan.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Dapagliflozin.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Diclofenamide.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Desflurane.Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Diclofenamide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Diclofenamide.Approved, Vet Approved
DextroamphetamineDiclofenamide may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DiethylpropionDiclofenamide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Diclofenamide.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Diclofenamide.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Diclofenamide.Approved
DorzolamideThe risk or severity of adverse effects can be increased when Dorzolamide is combined with Diclofenamide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Diclofenamide.Approved
DuloxetineDiclofenamide may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Diclofenamide.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Enalaprilat.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Diclofenamide.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Diclofenamide.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Diclofenamide.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Diclofenamide.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Diclofenamide.Withdrawn
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Diclofenamide.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Fenoldopam.Approved
FimasartanThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Fimasartan.Approved
FlecainideThe serum concentration of Flecainide can be increased when it is combined with Diclofenamide.Approved, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Diclofenamide.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Fosphenytoin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Diclofenamide.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Diclofenamide.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Halothane.Approved, Vet Approved
HexamethylenetetramineThe therapeutic efficacy of Hexamethylenetetramine can be decreased when used in combination with Diclofenamide.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Diclofenamide.Approved
HydralazineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Diclofenamide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Hydroflumethiazide.Approved
Hydroxyamphetamine hydrobromideDiclofenamide may decrease the excretion rate of Hydroxyamphetamine hydrobromide which could result in a higher serum level.Approved
IloprostThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Diclofenamide.Approved
IndoraminThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Indoramin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Diclofenamide.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Diclofenamide.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Diclofenamide.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Diclofenamide.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Diclofenamide.Approved
LacidipineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Lacidipine.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Levobupivacaine.Approved
LevodopaDiclofenamide may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Levosimendan.Approved, Investigational
LisdexamfetamineDiclofenamide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Diclofenamide.Approved, Investigational
LithiumThe serum concentration of Lithium can be decreased when it is combined with Diclofenamide.Approved
LofexidineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Lofexidine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Diclofenamide.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Diclofenamide.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Mecamylamine.Approved
MemantineDiclofenamide may decrease the excretion rate of Memantine which could result in a higher serum level.Approved, Investigational
MephedroneDiclofenamide may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephentermineDiclofenamide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Diclofenamide.Approved
MetforminThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Metformin.Approved
MethamphetamineDiclofenamide may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Diclofenamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Diclofenamide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Diclofenamide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Diclofenamide.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Diclofenamide.Approved
MetipranololThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Diclofenamide.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Diclofenamide.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Diclofenamide.Approved
MMDADiclofenamide may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Diclofenamide.Approved
MorphineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Nadolol.Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Diclofenamide.Investigational
NebivololThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Nebivolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Diclofenamide.Approved
NicorandilNicorandil may increase the hypotensive activities of Diclofenamide.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Diclofenamide.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Diclofenamide.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Diclofenamide.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Nitric Oxide.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Diclofenamide.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Diclofenamide.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Diclofenamide.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Obinutuzumab.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Diclofenamide.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Diclofenamide.Approved
OxprenololThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Diclofenamide.Approved
PenbutololThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Diclofenamide.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Diclofenamide.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Phenelzine.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Diclofenamide.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Phenoxybenzamine.Approved
PhentermineDiclofenamide may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
PhentolamineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Phentolamine.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Phenytoin.Approved, Vet Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Diclofenamide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Pipamperone.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Diclofenamide.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Primidone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Diclofenamide.Approved, Investigational
PseudoephedrineDiclofenamide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Diclofenamide.Approved, Investigational
QuinidineDiclofenamide may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Diclofenamide.Approved
RasagilineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Remifentanil.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Diclofenamide.Approved
RiociguatThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Riociguat.Approved
RisperidoneDiclofenamide may increase the hypotensive activities of Risperidone.Approved, Investigational
RitobegronDiclofenamide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Sacubitril.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Diclofenamide.Approved, Vet Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Diclofenamide.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Selegiline.Approved, Investigational, Vet Approved
SevofluraneThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Sevoflurane.Approved, Vet Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Diclofenamide.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Diclofenamide.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Sufentanil.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Diclofenamide.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Terazosin.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Diclofenamide.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Diclofenamide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Thioridazine.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Diclofenamide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Diclofenamide.Approved
TolazolineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Tolcapone.Approved, Withdrawn
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Diclofenamide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Diclofenamide.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Diclofenamide.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Diclofenamide.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Diclofenamide.Approved
Food InteractionsNot Available
References
Synthesis Reference

Schultz,E.M.; U.S.Patent 2,835,702; May 20, 1958; assigned to Merck & Co.,Inc.

General References
  1. Tawil R, McDermott MP, Brown R Jr, Shapiro BC, Ptacek LJ, McManis PG, Dalakas MC, Spector SA, Mendell JR, Hahn AF, Griggs RC: Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. Ann Neurol. 2000 Jan;47(1):46-53. [PubMed:10632100 ]
  2. Okada S, Izumi W, Murai M, Komatsu H, Ishimitsu S: [Diclofenamide Reference Standard (Control 891) of National Institute of Hygienic Sciences]. Eisei Shikenjo Hokoku. 1991;(109):148-50. [PubMed:1364383 ]
External Links
ATC CodesS01EC02
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9913
Blood Brain Barrier+0.8167
Caco-2 permeable-0.54
P-glycoprotein substrateNon-substrate0.8835
P-glycoprotein inhibitor INon-inhibitor0.9593
P-glycoprotein inhibitor IINon-inhibitor0.9922
Renal organic cation transporterNon-inhibitor0.9254
CYP450 2C9 substrateNon-substrate0.8101
CYP450 2D6 substrateNon-substrate0.9085
CYP450 3A4 substrateNon-substrate0.7198
CYP450 1A2 substrateNon-inhibitor0.9044
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.957
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9691
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8017
Ames testNon AMES toxic0.7954
CarcinogenicityNon-carcinogens0.7986
BiodegradationNot ready biodegradable0.9872
Rat acute toxicity2.1828 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9697
hERG inhibition (predictor II)Non-inhibitor0.9558
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral50 mg/1
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point228.5Schultz,E.M.; U.S.Patent 2,835,702; May 20, 1958; assigned to Merck & Co.,Inc.
logP0.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.398 mg/mLALOGPS
logP0.92ALOGPS
logP0.39ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)7.94ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area120.32 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity59.98 m3·mol-1ChemAxon
Polarizability25.04 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentBenzenesulfonamides
Alternative Parents
Substituents
  • Benzenesulfonamide
  • 1,2-dichlorobenzene
  • Halobenzene
  • Chlorobenzene
  • Aryl halide
  • Aryl chloride
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organochloride
  • Organohalogen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name:
CA1
Uniprot ID:
P00915
Molecular Weight:
28870.0 Da
References
  1. Winum JY, Casini A, Mincione F, Starnotti M, Montero JL, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. Bioorg Med Chem Lett. 2004 Jan 5;14(1):225-9. [PubMed:14684332 ]
  2. Lindskog S: Structure and mechanism of carbonic anhydrase. Pharmacol Ther. 1997;74(1):1-20. [PubMed:9336012 ]
  3. Nishimori I, Minakuchi T, Onishi S, Vullo D, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors. J Med Chem. 2007 Jan 25;50(2):381-8. [PubMed:17228881 ]
  4. Giacomotto J, Pertl C, Borrel C, Walter MC, Bulst S, Johnsen B, Baillie DL, Lochmuller H, Thirion C, Segalat L: Evaluation of the therapeutic potential of carbonic anhydrase inhibitors in two animal models of dystrophin deficient muscular dystrophy. Hum Mol Genet. 2009 Nov 1;18(21):4089-101. doi: 10.1093/hmg/ddp358. Epub 2009 Jul 31. [PubMed:19648295 ]
  5. Cleland JC, Griggs RC: Treatment of neuromuscular channelopathies: current concepts and future prospects. Neurotherapeutics. 2008 Oct;5(4):607-12. doi: 10.1016/j.nurt.2008.09.001. [PubMed:19019313 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Molecular Weight:
29245.895 Da
References
  1. Mincione F, Scozzafava A, Supuran CT: The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des. 2008;14(7):649-54. [PubMed:18336310 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid.
Gene Name:
CA4
Uniprot ID:
P22748
Molecular Weight:
35032.075 Da
References
  1. Mincione F, Scozzafava A, Supuran CT: The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des. 2008;14(7):649-54. [PubMed:18336310 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide.
Gene Name:
CA7
Uniprot ID:
P43166
Molecular Weight:
29658.235 Da
References
  1. Mincione F, Scozzafava A, Supuran CT: The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des. 2008;14(7):649-54. [PubMed:18336310 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23